(Kunming, October 24, 2025) – Yuxi Walvax Biotechnology Co., Ltd., a subsidiary of Walvax Biotechnology Co., Ltd. ("Walvax"), and Pharmaniaga Lifescience Sdn. Bhd. (“PLS”), a wholly-owned subsidiary of Pharmaniaga Berhad of Malaysia signed an agreement recently, regarding the finished product distribution and local production of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ("13-valent Pneumococcal Conjugate Vaccine" or "PCV-13") in Malaysia. Under the terms of the agreement, PLS will serve as Walvax's partner in Malaysia to jointly advance the technology transfer, local production, commercialization and distribution of the PCV-13.

Following in-depth business negotiations and technical exchanges, Walvax and PLS reached consensus on core terms including business models and technology transfer plans, ultimately leading to the signing of the agreement.

PCV-13 effectively prevents invasive diseases caused by pneumococcal bacteria, including pneumonia, meningitis, and bacteremia, providing critical protection for infants and young children under six years of age, particularly against drug-resistant pneumococcal strains. With approximately 500,000 newborns annually in Malaysia, and based on Ministry of Health procurement data indicating an annual PCV vaccine demand of approximately 1.5 million doses, the market demand remains stable. This local production project will satisfy domestic and regional vaccine needs, significantly enhance vaccine supply stability and accessibility, enabling more children to receive safe and effective immunization protection in a timely manner.

This collaboration represents an important achievement in Walvax's strategy to bring “Chinese pharmaceuticals” overseas and is the 6th local production project for Walvax’s 13-valent Pneumococcal Conjugate Vaccine, following Morocco, Indonesia, Egypt, Mexico and Bangladesh. In addition, the collaboration was facilitated by Dubai-based company RevonBio FZ-LLC through its strategic network.

About Pharmaniaga Berhad

Pharmaniaga Berhad is Malaysia’s largest listed integrated healthcare company. Its wholly-owned subsidiary, Pharmaniaga LifeScience Sdn Bhd received EU Good Manufacturing Practice certification in 2013. The facility produces sterile small volume injectables and, in 2021, became the first pharmaceutical company in Malaysia with human vaccine filling capabilities.

About Walvax

Founded in 2001, Walvax is mainly engaged in research and development, manufacture and distribution of human vaccines. It is the first company in China and the second globally to independently develop and successfully launch a 13-valent pneumococcal conjugate vaccine. This product has maintained a leading market share in China continuously since 2021.

About RevonBio FZ-LLC

RevonBio FZ-LLC, a Dubai-based company, is a commercial biologics enterprise with offices in China. The company is dedicated to supporting Chinese biopharmaceutical companies in commercializing their products across emerging markets.